(Press-News.org) This spring, a team of researchers has released results from an eight-year study that shows improved survival rates for women diagnosed with ovarian cancer who undergo cancer tumor testing to determine the best treatment.
Part of the team was Richard G. Moore, MD, director of the Center for Biomarkers and Emerging Technologies and a gynecologic oncologist with the Program in Women's Oncology at Women & Infants Hospital of Rhode Island.
"Essentially, we have demonstrated that by using a tissue sample from the patient's tumor and a chemoresponse assay, we are able to determine which treatment may or may not work for her," Dr. Moore explains of the study, which was presented at a recent meeting of the Society of Gynecologic Oncology and in the trade publication Cure.
"This study shows that a woman with recurrent ovarian cancer could benefit from having a biopsy and chemosensitivity testing. The results from such testing will allow for the identification of chemotherapeutics that are active against the patient's disease and those that are not resulting in decreased toxicity from ineffective treatments. Learning that personal directed therapies may improve overall survival for these patients made this the first study in two decades to show a significant increase in survival in recurrent ovarian cancer."
The study, launched in 2004, included 283 women. Of those, 262 had successful biopsies which were tested in vitro, or in a test tube. The assay ChemoFx®, by Precision Therapeutics, tested up to 15 approved treatment regimens on the samples, identifying chemotherapy drugs and regimens to which each tumor might be sensitive. The study was non-interventional, meaning that physicians chose the treatment regimens without knowing of the assay results. The researchers then evaluated the assay's result against actual patient outcomes.
"The assay identified at least one treatment to which the tumor would be sensitive in 52% of patients in the study," Dr. Moore says. "Overall, median survival was 37.5 months for patients with treatment-sensitive tumors, compared to 23.9 months for intermediate and resistant tumors."
Assay-directed therapy has long been debated among oncologists, he continues. Such debate provided the impetus for this study.
###
About Women & Infants Hospital
Women & Infants Hospital of Rhode Island, a Care New England hospital, is one of the nation's leading specialty hospitals for women and newborns. The primary teaching affiliate of The Warren Alpert Medical School of Brown University for obstetrics, gynecology and newborn pediatrics, as well as a number of specialized programs in women's medicine, Women & Infants is the ninth largest stand-alone obstetrical service in the country with nearly 8,400 deliveries per year. In 2009, Women & Infants opened the country's largest, single-family room neonatal intensive care unit.
New England's premier hospital for women and newborns, Women & Infants and Brown offer fellowship programs in gynecologic oncology, maternal-fetal medicine, urogynecology and reconstructive pelvic surgery, neonatal-perinatal medicine, pediatric and perinatal pathology, gynecologic pathology and cytopathology, and reproductive endocrinology and infertility. It is home to the nation's only mother-baby perinatal psychiatric partial hospital, as well as the nation's only fellowship program in obstetric medicine.
Women & Infants has been designated as a Breast Center of Excellence from the American College of Radiology; a Center for In Vitro Maturation Excellence by SAGE In Vitro Fertilization; a Center of Biomedical Research Excellence by the National Institutes of Health; and a Neonatal Resource Services Center of Excellence. It is one of the largest and most prestigious research facilities in high risk and normal obstetrics, gynecology and newborn pediatrics in the nation, and is a member of the National Cancer Institute's Gynecologic Oncology Group and the National Institutes of Health's Pelvic Floor Disorders Network.
About ChemoFx®
ChemoFx®, is a proprietary, CLIA-certified and commercially-available chemoresponse assay which measures an individual's tumor response to a range of therapeutic alternatives under consideration by the treating physician. By testing multiple chemotherapies on a patient's tumor cells before clinically treating a cancer patient, ChemoFx® helps determine the chemotherapies more likely to be effective and, therefore, provides valuable insights that help inform physicians' treatment decisions with a goal of improving patient outcomes.
Precision Therapeutics currently receives ChemoFx® specimens from 271 top medical institutions including 20 of the 21 National Comprehensive Cancer Network (NCCN) Member Institutions, and 8 of the US News and World Report Top 10 Hospitals for Cancer Care. Over 60,000 patient specimens to date have been tested with ChemoFx®.
About Precision Therapeutics
Precision Therapeutics, a leading life-science company based in Pittsburgh, Pennsylvania, is dedicated to utilizing precision medicine for personalized cancer care. Precision offers a portfolio of products developed to help guide physicians and patients with difficult clinical decisions throughout the cancer care continuum. The company's leading products for personalized cancer care include ChemoFx® and BioSpeciFx®, a select portfolio of clinically relevant molecular tests that provide information about drug response and patient prognosis. Additionally, in 2013 Precision is releasing two new gene signature products, under the GeneFx® brand. GeneFx Colon is a 634-transcript microarray assay that has been independently validated to predict risk of disease recurrence in stage II colon cancer patients. It is currently undergoing an additional independent validation using a large cooperative group cohort. GeneFx Lung is a 15-gene microarray assay that has been independently validated in 5 separate patient groups to predict risk of mortality in early stage non-small cell lung cancer (NSCLC), and may also be able to predict which of those patients will experience benefit from chemotherapy.
For more information, visit http://www.precisiontherapeutics.com or http://www.chemofx.com.
Research: Chemoresponse assay helps boost ovarian cancer survival
2013-04-25
ELSE PRESS RELEASES FROM THIS DATE:
Unique chemistry reveals eruption of ancient materials once at Earth's surface
2013-04-25
An international team of researchers, including Scripps Institution of Oceanography, UC San Diego, geochemist James Day, has found new evidence that material contained in oceanic lava flows originated in Earth's ancient Archean crust. These findings support the theory that much of the Earth's original crust has been recycled by the process of subduction, helping to explain how the Earth has formed and changed over time.
The Archean geologic eon, Earth's second oldest, dating from 3.8 to 2.5 billion years ago, is the source of the oldest exposed rock formations on the ...
Bold move forward in molecular analyses
2013-04-25
A dramatic leap forward in the ability of scientists to study the structural states of macromolecules such as proteins and nanoparticles in solution has been achieved by a pair of researchers with the U.S. Department of Energy (DOE)'s Lawrence Berkeley National Laboratory (Berkeley Lab). The researchers have developed a new set of metrics for analyzing data acquired via small angle scattering (SAS) experiments with X-rays (SAXS) or neutrons (SANS). Among other advantages, this will reduce the time required to collect data by up to 20 times.
"SAS is the only technique ...
Are living liver donors at risk from life-threatening 'near-miss' events?
2013-04-25
A study published in Liver Transplantation, a journal of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, reports that donor mortality is about 1 in 500 donors with living donor liver transplantation (LDLT). Research of transplant centers around the world found that those with more experience conducting live donor procedures had lower rates of aborted surgery and life-threatening "near-miss" events.
For patients with end-stage liver disease, liver transplantation is their only option to prolong life. However, ...
Thanks to rare alpine bacteria, researchers identify one of alcohol's key gateways to the brain
2013-04-25
AUSTIN, Texas — Thanks to a rare bacteria that grows only on rocks in the Swiss Alps, researchers at The University of Texas at Austin and the Pasteur Institute in France have been the first to identify how alcohol might affect key brain proteins.
It's a major step on the road to eventually developing drugs that could disrupt the interaction between alcohol and the brain.
"Now that we've identified this key brain protein and understand its structure, it's possible to imagine developing a drug that could block the binding site," said Adron Harris, professor of biology ...
Study: Teen years may be critical in later stroke risk
2013-04-25
MINNEAPOLIS – The teenage years may be a key period of vulnerability related to living in the "stroke belt" when it comes to future stroke risk, according to a new study published in the April 24, 2013, online issue of Neurology®, the medical journal of the American Academy of Neurology.
More people have strokes and die of strokes in the southeastern area known as the stroke belt than in the rest of the United States. So far, research has shown that only part of the difference can be explained by traditional risk factors such as diabetes and high blood pressure. Previous ...
Biogeographic barrier that protects Australia from avian flu does not stop Nipah virus
2013-04-25
An invisible barrier separates land animals in Australia from those in south-east Asia may also restrict the spillover of animal-borne diseases like avian flu, but researchers have found that fruit bats on either side of this line can carry Nipah virus, a pathogen that causes severe human disease. The findings are published April 24 in the open access journal PLOS ONE by Andrew Breed from the University of Queensland, Australia and colleagues from other institutions.
Previous studies have suggested that this biogeographic boundary, named Wallace's line, may have played ...
Body size conveyed by voice determines vocal attractiveness
2013-04-25
Deep male voices and high-pitched female voices are perceived as more attractive because listeners gauge the speaker's body size from the frequency of their voice, according to research published April 24 in the open access journal PLOS ONE by Yi Xu from University College London (UK) and colleagues.
Studies of animals and birds reveal that listeners can perceive a caller's body size and intension based on the frequency, voice quality and formant spacing of a call. For example, low frequency growls are more likely to indicate larger body size, dominance or a potential ...
Clenching right fist may give better grip on memory
2013-04-25
Clenching your right hand may help form a stronger memory of an event or action, and clenching your left may help you recollect the memory later, according to research published April 24 in the open access journal PLOS ONE by Ruth Propper and colleagues from Montclair State University.
Participants in the research study were split into groups and asked to first memorize, and later recall words from a list of 72 words. There were 4 groups who clenched their hands; One group clenched their right fist for about 90 seconds immediately prior to memorizing the list and then ...
Animal study finds deep brain stimulation reduces binge eating behavior
2013-04-25
Washington, DC — Stimulating a region of the brain known to be involved in reward decreases binge eating behavior in mice, according to a study published in the April 24 issue of The Journal of Neuroscience. The findings add to a growing body of evidence supporting the role of the brain’s reward system in driving the consumption of palatable food. It could one day pave the way for more effective and lasting treatments for obesity.
The numbers of people worldwide living with obesity continues to climb. Recent studies suggest that the consumption of high calorie ...
T2 Bio publishes data supporting diagnostic test T2Candida® in Science Translational Medicine
2013-04-25
Lexington, MA, April 24, 2013 (Embargoed until 2:00 PM US Eastern Time) – T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced the publication of research supporting the Company's flagship diagnostic test, T2Candida®, in Science Translational Medicine. The research highlights T2Candida as a breakthrough approach to rapid and sensitive identification of species-specific Candida, a sepsis-causing fungus, directly from whole blood in approximately three hours, or up to 25 times faster than the current gold standard of ...